Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-23T06:42:59.034Z Has data issue: false hasContentIssue false
  • English
  • Français

Costes y resultados del tratamiento con risperidona en la esquizofrenia en la República Checa

Published online by Cambridge University Press:  12 May 2020

L. Hosák  and
R. Bahbouh
L. Hosák
Affiliation:
Departamento de Psiquiatría, Universidad Carlos, 500 05Hradec Králové, República Checa
R. Bahbouh
Affiliation:
Departamento de Psicología, Universidad Carlos, Praga, República Checa
Get access

Resumen

El creciente coste de los productos farmacéuticos en la República Checa ha llevado a restricciones en la prescripción de los antipsicóticos atípicos más caros. El propósito del estudio era comparar los costes y los resultados de utilizar risperidona frente a los neurolépticos clásicos en el tratamiento de la esquizofrenia para ver si limitar el uso de los antipsicóticos más recientes suponía algún beneficio. Se trató con risperidona a 67 pacientes (39 mujeres) con una edad media de 34,6 años (DT= 9,74) que sufrían esquizofrenia o trastorno esquizoafectivo, mientras que 67 pacientes (39 mujeres) con el mismo diagnóstico con una edad media de 35,7 años (DT = 9,91) recibían neurolépticos estándar. Se evaluaron retrospectivamente los costes y los desenlaces médicos anuales directos (indicados por la puntuación media de la Evaluación de la Actividad Global) en un estudio al descubierto de intención de tratamiento resumiendo las historias médicas ambulatorias psiquiátricas. Los resultados no fueron significativamente diferentes entre los grupos de tratamiento, aunque el tratamiento de risperidona era significativamente más caro que la terapia con neurolépticos estándar. Este resultado, que parece no estar de acuerdo con las publicaciones, era consecuencia del bajo coste de la mano de obra en la República Checa. La diferencia entre los tratamientos seguidos en los costes directos probablemente se hará insignificante en el futuro, cuando la economía del país esté más desarrollada.

Keywords

esquizofreniarisperidonaneurolépticos estándarcosteevolución
Type
Artículo Original
Information
European Psychiatry (Ed. Española) , Volume 9 , Issue 8 , November 2002 , pp. 520 - 528
Copyright
Copyright © European Psychiatric Association 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

HosákL, BahbouhR.Costes y resultados del tratamiento con risperidona en la esquizofrenia en la República Checa. Eur Psychiatry2002; 17: 213-21.

References

Bibliografía

Aronson, SM.Cost-effectiveness and quality of life in psychosis: the pharmacoeconomics of risperidone. Clin Ther 1997;19:139–47.CrossRefGoogle ScholarPubMed
Borison, RL, Pathiraja, AP, Diamond, BI, Meibach, RC.Risperidone: clinical safety and efflcacy in schizophrenia. Psychopharmacol Bull 1992;28:213–8.Google Scholar
Chouinard, G, Kopala, L, Labelle, A, Beauclair, L, Johnson, SV, Singh, KI.Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia, The RISCAN-3 Study Group. Can J Psychiatry 1998;43:1018–25.Google ScholarPubMed
Čéská lékaíska komora a Ministerstvo zdravotnictví ČR. Seznam zdravotních vykonů s bodovymi hodnotami 1998. 1. vydání Praha: Strategie; 1998.Google Scholar
Český statistický úŕad. Statistická roćenka České republiky. 1. vydání. Praha: Český statistický úŕad; 1998.Google Scholar
Davies, A, Adena, MA, Keks, NA, Catts, SV, Lambeit, T, Schweitzer, I.Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety. Clin Ther 1998;20:58–71.CrossRefGoogle ScholarPubMed
Davies, LM, Drummond, MF.Economics and schizophrenia: the real cost. Br J Psychiatry 1994;l65(Suppl 25):18–21.CrossRefGoogle Scholar
Davies, A, Langley, PC, Keks, NA, Catts, SV, Lambert, T, Schweitzer, I.Risperidone versus haloperidol: II. Cost-effectiveness. Clin Ther 1998;20:196–213.Google ScholarPubMed
De Oliveira, IR, Miranda-Scippa, AM, De Sena, EP, Pereira, EL, Ribeiro, MG, De Castroe-Silva, E, et al.Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety. J Clin Pharm Ther 1996;21:349–58.Google ScholarPubMed
Finley, PR, Sommer, BR, Corbitt, JL, Brunson, GH, Lum, BL.Risperidone: clinical outcome predictors and cost-effectiveness in a naturalistic setting. Psychopharmacol Bull 1998;34:75–81.Google Scholar
Frarěk, J.1. Farmakoekonomická konference. Medícina 1998;5:1–2.Google Scholar
Gallhofer, B, Bauer, U, Lis, S, Krieger, S, Gruppe, H.Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 1996;6(Suppl 2):S13–20.CrossRefGoogle ScholarPubMed
Galvin, PM, Knezek, LD, Rush, AJ, Toprac, MG, Johnson, B.Clinical and economic impact of newer versus older antipsychotic medications in a community mental health center. Clin Ther 1999;21:1105–16.CrossRefGoogle Scholar
Green, MF, Marshall, BD x, Wirshing, WC, Ames, D, Marder, SR, McGurk, S.et al.Does risperidone improve verbal working memory in treatment-resistant schizophrenia. Am J Psychiatry 1997;154:799–804.Google ScholarPubMed
Gutierrez-Esteinou, R, Grebb, JA.Risperidone: an analysis of the first 3 years in general use. Int Clin Psychopharmacol 1997;12(Suppl 4):S3–S10.CrossRefGoogle ScholarPubMed
Hosák, L.Farmakoekonomika v psychiatrii. 1. vydání. Praha: Galén; 2000.Google Scholar
Iskedjian, M, Hux, M, Remington, GJ.The Canadian Experience with risperidone for the treatment of schizophrenia: an overview. J Psychiatry Neurosci 1998;23:229–39.Google ScholarPubMed
Karen, P., Filip, V.Léčba schizofrenie risperidonem z farmakoekonomického hlediska. 1. vydání. Praha: Pharmnet; 1996.Google Scholar
Kee, KS, Kem, RS, Marshall, BD Jr, Green, MF.Risperidone versus haloperidol for perception of emotion in treatmentresistant schizophrenia: preliminary findings. Schizophr Res 1998;31:159–65.Google Scholar
Kem, RS, Green, MF, Marshall, BD Jr, Wirshing, WC, Wirshing, D, McGurk, SR, et al.Risperidone versus haloperidol on secondary memory: can newer medications aid leaming. Schizophr Bull 1999;25:223–32.Google Scholar
Knapp, M.Costs of schizophrenia. Br J Psychiatry 1997;171:509–18.Google ScholarPubMed
Kubek, M.Pozadujte vyšší mzdy. Tempus Medicorum 2000;9:18.Google Scholar
Marder, SR, Davis, JM, Chouinard, G.The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58:538–46.CrossRefGoogle ScholarPubMed
Möller, HJ, Bäuml, J, Ferrero, F, Fuger, J, Geretsegger, C, Kasper, S, et al.Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria and Switzerland. Eur Arch Psychiatry Clin Neurosci 1997;247:291–6.Google ScholarPubMed
Morris, S, Hogan, T, McGuire, A.The cost-effectiveness of clozapine. A survey of the literature. Clin Drug Invest 1998;15:1.37–52.CrossRefGoogle ScholarPubMed
Nightengale, BS, Crumly, JM, Liao, J, Lawrence, BJ, Jacobs, EW.Economic outcomes of antipsychotic agents in a Medicaid population: traditional agents vs. risperidone. Psychopharmacol Bull 1998;34:373–82.Google Scholar
Percudani, M, Fattore, G, Galletta, J, Mita, PT, Consinni, A, Altamura, AC.Health care cost of therapy-refractory schizophrenic patients treated with clozapine: a study in a community psychiatric services in Italy. Acta Psychiatr Scand 1999;99:274–80.CrossRefGoogle Scholar
Revicki, DA.Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Schizophr Res 1999;35(Suppl):S101–9.CrossRefGoogle ScholarPubMed
Revicki, DA, Luce, BR.Pharmacoeconomic research applied to psychopharmacology development and evaluation. Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry. Psychopharmacol Bull 1995;31:57–65.Google Scholar
Rossi, A, Mancini, F, Stratta, P, Mattei, P, Gismondi, R, Pozzi, F, et al.Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatr Scand 1997;95:40–3.Google Scholar
Schiller, MJ, Shumway, M, Hargreaves, WA.Treatment costs and patient outcomes with use of risperidone in a public mental health setting. Psychiatr Serv 1999;50:228–32.CrossRefGoogle Scholar
Sménný kurz. Hospodaĭské noviny 1999;43(Suppl (No.l, January 4th, 1999)):S1.Google Scholar
Smith, RC, Chua, JW, Lipetsker, B, Bhattacharyia, A.Eificacy of risperidone in reducting positive and negative symptoms in medication-refractory schizophrenia: an open prospective study. J Clin Psychiatry 1996;57:460–6.CrossRefGoogle Scholar
Song, F.Risperidone in the treatment of schizophrenia: a metaanalysis of randomized controlled triais. J Psychopharmacol 1997;11:65–71.CrossRefGoogle Scholar
Světová zdravotnická oiganizace, Mezinárodní klasifikace nemocí. 10. revize. Duševní poruchy a poruchy chovani. 1. vydani. Praha: Psychiatricke centrum Praha; 1992.Google Scholar
Škoda, C, Papeš, Z, Baudiš, P, Eis, Z, Probstová, V.Kvantifikace důsledků transformace zdravotnictví na poskytování psychiatrické péče v ČR. Ekonomické aspekty. 1. vydání. Praha: Psychiatricke centrum Praha; 1998.Google Scholar
Viale, G, Mechling, L, Maislin, G, Durkin, M, Engelhart, L, Lawrence, BJ.Impact of risperidone on the use of mental health care resources. Psychiatr Serv 1997;48:1153–9.Google ScholarPubMed
Všeobecná zdravotní pojištovna. ČR. Číselníky VZP. 1. vydání. Praha: Všeobecná zdravotni pojištovnaČR; 1997.Google Scholar
Wyatt, RJ, Henter, I, Leary, MC.An economic evaluation of schizophrenia 1991. Soc Psychiatry Psychiatr Epidemiol 1995;30:196–205.Google ScholarPubMed
Ztráta ministerských nemocnic se prohlubuje. Zdravotnicke noviny 2001;20:20.Google Scholar